Cargando…

Systematic Pan-Cancer Analysis and Experimental Verification Identify FOXA1 as an Immunological and Prognostic Biomarker in Epithelial Ovarian Cancer

BACKGROUND: Epithelial ovarian cancer (EOC) has the lowest survival rate among female reproductive cancers present with symptoms of aggressive malignancies, poor prognosis, drug resistance and postoperative recurrence. The majority of patients with EOC are diagnosed at an advanced stage due to the t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Kai, Guan, Chenan, Yu, Junhui, Chen, Xing, Shang, Xianwen, Mei, Shuangshuang, Feng, Xingjun, Zheng, Lingzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646314/
https://www.ncbi.nlm.nih.gov/pubmed/36393971
http://dx.doi.org/10.1155/2022/9328972
_version_ 1784827137331560448
author Wang, Kai
Guan, Chenan
Yu, Junhui
Chen, Xing
Shang, Xianwen
Mei, Shuangshuang
Feng, Xingjun
Zheng, Lingzhi
author_facet Wang, Kai
Guan, Chenan
Yu, Junhui
Chen, Xing
Shang, Xianwen
Mei, Shuangshuang
Feng, Xingjun
Zheng, Lingzhi
author_sort Wang, Kai
collection PubMed
description BACKGROUND: Epithelial ovarian cancer (EOC) has the lowest survival rate among female reproductive cancers present with symptoms of aggressive malignancies, poor prognosis, drug resistance and postoperative recurrence. The majority of patients with EOC are diagnosed at an advanced stage due to the therapeutic challenges including lack of early diagnosis and effective therapeutic targets for EOC. METHODS: Pan-cancer analyses were performed to explore the features of forkhead-box (FOX) A1 (FOXA1) using data from TCGA and GTEx databases. R package “clusterprofiler” was used to perform the enrichment analysis of FOXA1 in EOC. Data downloaded from Drug Sensitivity in Cancer (GDSC) database were used to evaluate the association between FOXA1 and antitumor drug sensitivity. In experimental verification, FOXA1 expression was detected using qRT-PCR and western blot assays. Western blot, immunofluorescence staining, and Transwell assays were used to assess the influence of FOXA1 silencing on epithelial-mesenchymal transition (EMT) of EOC cells. RESULTS: We found that FOXA1 was highly expressed in EOC and predicted poorer survival of EOC patients. We observed that FOXA1 expression was positively correlated EMT-related pathways. Through experimental verification, we found the underlying function of FOXA1 to promote EMT in ovarian cancers. The results from western blot, immunofluorescence staining, and Transwell assays showed that FOXA1 silencing impeded the progression of EMT and invasiveness of the cancer cells. Furthermore, CCK-8 and invasion assays suggested that siRNA-FOXA1 attenuated the ability of cancer cells to metastasize and proliferate. Dual-luciferase reporter assays confirmed the binding activity of FOXA1 to the promoter of connective tissue growth factor (CTGF). In addition, we found that FOXA1 was closely correlated immunosuppressive microenvironment of EOC. High FOXA1 expression may contribute to the resistance of many anticancer drugs. CONCLUSIONS: Our results predict and validate the function of FOXA1 in promoting EMT and the progression of disease in EOC. Targeting FOXA1 may improve the sensitivity of EOC treatment.
format Online
Article
Text
id pubmed-9646314
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-96463142022-11-15 Systematic Pan-Cancer Analysis and Experimental Verification Identify FOXA1 as an Immunological and Prognostic Biomarker in Epithelial Ovarian Cancer Wang, Kai Guan, Chenan Yu, Junhui Chen, Xing Shang, Xianwen Mei, Shuangshuang Feng, Xingjun Zheng, Lingzhi Dis Markers Research Article BACKGROUND: Epithelial ovarian cancer (EOC) has the lowest survival rate among female reproductive cancers present with symptoms of aggressive malignancies, poor prognosis, drug resistance and postoperative recurrence. The majority of patients with EOC are diagnosed at an advanced stage due to the therapeutic challenges including lack of early diagnosis and effective therapeutic targets for EOC. METHODS: Pan-cancer analyses were performed to explore the features of forkhead-box (FOX) A1 (FOXA1) using data from TCGA and GTEx databases. R package “clusterprofiler” was used to perform the enrichment analysis of FOXA1 in EOC. Data downloaded from Drug Sensitivity in Cancer (GDSC) database were used to evaluate the association between FOXA1 and antitumor drug sensitivity. In experimental verification, FOXA1 expression was detected using qRT-PCR and western blot assays. Western blot, immunofluorescence staining, and Transwell assays were used to assess the influence of FOXA1 silencing on epithelial-mesenchymal transition (EMT) of EOC cells. RESULTS: We found that FOXA1 was highly expressed in EOC and predicted poorer survival of EOC patients. We observed that FOXA1 expression was positively correlated EMT-related pathways. Through experimental verification, we found the underlying function of FOXA1 to promote EMT in ovarian cancers. The results from western blot, immunofluorescence staining, and Transwell assays showed that FOXA1 silencing impeded the progression of EMT and invasiveness of the cancer cells. Furthermore, CCK-8 and invasion assays suggested that siRNA-FOXA1 attenuated the ability of cancer cells to metastasize and proliferate. Dual-luciferase reporter assays confirmed the binding activity of FOXA1 to the promoter of connective tissue growth factor (CTGF). In addition, we found that FOXA1 was closely correlated immunosuppressive microenvironment of EOC. High FOXA1 expression may contribute to the resistance of many anticancer drugs. CONCLUSIONS: Our results predict and validate the function of FOXA1 in promoting EMT and the progression of disease in EOC. Targeting FOXA1 may improve the sensitivity of EOC treatment. Hindawi 2022-11-02 /pmc/articles/PMC9646314/ /pubmed/36393971 http://dx.doi.org/10.1155/2022/9328972 Text en Copyright © 2022 Kai Wang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wang, Kai
Guan, Chenan
Yu, Junhui
Chen, Xing
Shang, Xianwen
Mei, Shuangshuang
Feng, Xingjun
Zheng, Lingzhi
Systematic Pan-Cancer Analysis and Experimental Verification Identify FOXA1 as an Immunological and Prognostic Biomarker in Epithelial Ovarian Cancer
title Systematic Pan-Cancer Analysis and Experimental Verification Identify FOXA1 as an Immunological and Prognostic Biomarker in Epithelial Ovarian Cancer
title_full Systematic Pan-Cancer Analysis and Experimental Verification Identify FOXA1 as an Immunological and Prognostic Biomarker in Epithelial Ovarian Cancer
title_fullStr Systematic Pan-Cancer Analysis and Experimental Verification Identify FOXA1 as an Immunological and Prognostic Biomarker in Epithelial Ovarian Cancer
title_full_unstemmed Systematic Pan-Cancer Analysis and Experimental Verification Identify FOXA1 as an Immunological and Prognostic Biomarker in Epithelial Ovarian Cancer
title_short Systematic Pan-Cancer Analysis and Experimental Verification Identify FOXA1 as an Immunological and Prognostic Biomarker in Epithelial Ovarian Cancer
title_sort systematic pan-cancer analysis and experimental verification identify foxa1 as an immunological and prognostic biomarker in epithelial ovarian cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646314/
https://www.ncbi.nlm.nih.gov/pubmed/36393971
http://dx.doi.org/10.1155/2022/9328972
work_keys_str_mv AT wangkai systematicpancanceranalysisandexperimentalverificationidentifyfoxa1asanimmunologicalandprognosticbiomarkerinepithelialovariancancer
AT guanchenan systematicpancanceranalysisandexperimentalverificationidentifyfoxa1asanimmunologicalandprognosticbiomarkerinepithelialovariancancer
AT yujunhui systematicpancanceranalysisandexperimentalverificationidentifyfoxa1asanimmunologicalandprognosticbiomarkerinepithelialovariancancer
AT chenxing systematicpancanceranalysisandexperimentalverificationidentifyfoxa1asanimmunologicalandprognosticbiomarkerinepithelialovariancancer
AT shangxianwen systematicpancanceranalysisandexperimentalverificationidentifyfoxa1asanimmunologicalandprognosticbiomarkerinepithelialovariancancer
AT meishuangshuang systematicpancanceranalysisandexperimentalverificationidentifyfoxa1asanimmunologicalandprognosticbiomarkerinepithelialovariancancer
AT fengxingjun systematicpancanceranalysisandexperimentalverificationidentifyfoxa1asanimmunologicalandprognosticbiomarkerinepithelialovariancancer
AT zhenglingzhi systematicpancanceranalysisandexperimentalverificationidentifyfoxa1asanimmunologicalandprognosticbiomarkerinepithelialovariancancer